Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor–tezacaftor–ivacaftor, Germany, 2012–2021

Cystic fibrosis (CF) is an incurable, autosomal recessive multisystem disorder that is associated with multiple complications, in particular progressive lung disease, chronic pulmonary infections, respiratory failure and reduced life expectancy [1, 2]. In this regard, lung transplantation is an established treatment option for end-stage CF lung disease, aiming to improve both quality of life and survival [3]. This study observed a pronounced decline of CF-related lung transplants up to −83% in 2021 compared to the mean number in the period between 2012 and 2019, following the broad accessibility of elexacaftor-tezacaftor-ivacaftor in Germany in August 2020 https://bit.ly/3Pl7N9Y